Venetoclax + Dexamethasone
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Multiple Myeloma
Conditions
Relapsed/Refractory Multiple Myeloma
Trial Timeline
Oct 10, 2012 → Nov 29, 2021
NCT ID
NCT01794520About Venetoclax + Dexamethasone
Venetoclax + Dexamethasone is a phase 1/2 stage product being developed by AbbVie for Relapsed/Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT01794520. Target conditions include Relapsed/Refractory Multiple Myeloma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Multiple Myeloma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01794520 | Phase 1/2 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Multiple Myeloma